Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models

Science Advances

Volumn 5, Issue 1, 2019, Pages

  Elliott, Mark ^a   Favre Guilmard, Christine ^a   Liu, Sai Man ^a   Maignel, Jacquie ^a   Masuyer, Geoffrey ^b   Beard, Matthew ^a   Boone, Christopher ^c   Carré, Denis ^a   Kalinichev, Mikhail ^a   Lezmi, Stephane ^a   Mir, Imran ^a   Nicoleau, Camille ^a   Palan, Shilpa ^a   Perier, Cindy ^a   Raban, Elsa ^a   Zhang, Sicai ^c   Dong, Min ^c   Stenmark, Pål ^b,d   Krupp, Johannes ^a  

^a IPSEN   (France)

^b STOCKHOLM UNIVERSITY   (Sweden)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

NEURONS; STEM CELLS;

BOTULINUM NEUROTOXINS; CLINICAL EFFICACY; COCRYSTAL STRUCTURE; HUMAN RECEPTORS; HUMAN-INDUCED PLURIPOTENT STEM CELLS; SURFACE RECEPTORS; SYNAPTOTAGMINS; TRANSGENIC MICE;

RECOMBINANT PROTEINS;

BOTULINUM TOXIN A; BOTULINUM TOXIN B; GLYCINE; RECOMBINANT PROTEIN; SYNAPTOTAGMIN II; SYT2 PROTEIN, HUMAN;

ANIMAL; C57BL MOUSE; CHEMISTRY; DRUG EFFECT; FEMALE; GENETICS; HUMAN; INDUCED PLURIPOTENT STEM CELL; LEPORIDAE; MALE; METABOLISM; MUTATION; NERVE CELL; PROTEIN ENGINEERING; SKELETAL MUSCLE; SMOOTH MUSCLE; SPRAGUE DAWLEY RAT; STATIC ELECTRICITY; TRANSGENIC MOUSE; X RAY CRYSTALLOGRAPHY;

ANIMALS; BOTULINUM TOXINS, TYPE A; CRYSTALLOGRAPHY, X-RAY; FEMALE; GLYCINE; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MALE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUSCLE, SKELETAL; MUSCLE, SMOOTH; MUTATION; NEURONS; PROTEIN ENGINEERING; RABBITS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; STATIC ELECTRICITY; SYNAPTOTAGMIN II;

EID: 85060037659     PISSN: None     EISSN: 23752548     Source Type: Journal    
DOI: 10.1126/sciadv.aau7196     Document Type: Article

References (45)

1. S. Chen, Clinical uses of botulinum neurotoxins: Current indications, limitations and future developments. Toxins 4, 913–939 (2012).
2. D. Dressler, Clinical applications of botulinum toxin. Curr. Opin. Microbiol. 15, 325–336 (2012).
3. J. J. Chen, K. Dashtipour, Abo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: A primer. Pharmacotherapy 33, 304–318 (2013).
4. O. Lange, H. Bigalke, R. Dengler, F. Wegner, M. deGroot, K. Wohlfarth, Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: Much ado about nothing? Clin. Neuropharmacol. 32, 213–218 (2009).
5. C. L. Comella, J. Jankovic, K. M. Shannon, J. Tsui, M. Swenson, S. Leurgans, W. Fan, Dystonia Study Group, Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 65, 1423–1429 (2005).
6. J. Ramirez-Castaneda, J. Jankovic, C. Comella, K. Dashtipour, H. H. Fernandez, Z. Mari, Diffusion, spread, and migration of botulinum toxin. Mov. Disord. 28, 1775–1783 (2013).
7. M. A. Brodsky, D. M. Swope, D. Grimes, Diffusion of botulinum toxins. Tremor Other Hyperkinet. Mov. 2, tre-02-85-417-1 (2012).
8. A. R. Bentivoglio, A. Del Grande, M. Petracca, T. Ialongo, L. Ricciardi, Clinical differences between botulinum neurotoxin type A and B. Toxicon 107, 77–84 (2015).
9. R. R. Sloop, B. A. Cole, R. O. Escutin, Human response to botulinum toxin injection: Type B compared with type A. Neurology 49, 189–194 (1997).
10. T. Nishiki, Y. Kamata, Y. Nemoto, A. Omori, T. Ito, M. Takahashi, S. Kozaki, Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes. J. Biol. Chem. 269, 10498–10503 (1994).
11. M. Dong, D. A. Richards, M. C. Goodnough, W. H. Tepp, E. A. Johnson, E. R. Chapman, Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J. Cell Biol. 162, 1293–1303 (2003).
12. +- triggering of neurotransmitter release in central and neuromuscular synapses. J. Neurosci. 26, 13493–13504 (2006).
13. L. Peng, R. P.-A. Berntsson, W. H. Tepp, R. M. Pitkin, E. A. Johnson, P. Stenmark, M. Dong, Botulinum neurotoxin D-C uses synaptotagmin I and II as receptors, and human synaptotagmin II is not an effective receptor for type B, D-C and G toxins. J. Cell Sci. 125, 3233–3242 (2012).
14. J. Strotmeier, G. Willjes, T. Binz, A. Rummel, Human synaptotagmin-II is not a high affinity receptor for botulinum neurotoxin B and G: Increased therapeutic dosage and immunogenicity. FEBS Lett. 586, 310–313 (2012).
15. R. P. A. Berntsson, L. Peng, M. Dong, P. Stenmark, Structure of dual receptor binding to botulinum neurotoxin B. Nat. Commun. 4, 2058 (2013).
16. L. Tao, L. Peng, R. P.-A. Berntsson, S. M. Liu, S. Park, F. Yu, C. Boone, S. Palan, M. Beard, P.-E. Chabrier, P. Stenmark, J. Krupp, M. Dong, Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors. Nat. Commun. 8, 53 (2017).
17. R. C. M. Whitemarsh, M. J. Strathman, L. G. Chase, C. Stankewicz, W. H. Tepp, E. A. Johnson, S. Pellett, Novel application of human neurons derived from induced pluripotent stem cells for highly sensitive botulinum neurotoxin detection. Toxicol. Sci. 126, 426–435 (2012).
18. J. I. M. van Uhm, G. M. A. Beckers, W. J. van der Laarse, E. J. H. Meuleman, A. A. Geldof, J. A. Nieuwenhuijzen, Development of an in vitro model to measure bioactivity of botulinum neurotoxin A in rat bladder muscle strips. BMC Urol. 14, 37 (2014).
19. J. Maignel-Ludop, M. Huchet, J. Krupp, Botulinum Neurotoxins Serotypes A and B induce paralysis of mouse striated and smooth muscles with different potencies. Pharmacol. Res. Perspect. 5, e00289 (2017).
20. K. R. Aoki, A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon 39, 1815–1820 (2001).
21. Y. Torii, Y. Goto, S. Nakahira, S. Kozaki, R. Kaji, A. Ginnaga, Comparison of systemic toxicity between botulinum toxin subtypes A1 and A2 in mice and rats. Basic Clin. Pharmacol. Toxicol. 116, 524–528 (2015).
22. G. G. Schiavo, F. Benfenati, B. Poulain, O. Rossetto, P. Polverino de Laureto, B. R. DasGupta, C. Montecucco, Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 359, 832–835 (1992).
23. L. Peng, M. Adler, A. Demogines, A. Borrell, H. Liu, L. Tao, W. H. Tepp, S. C. Zhang, E. A. Johnson, S. L. Sawyer, M. Dong, Widespread sequence variations in VAMP1 across vertebrates suggest a potential selective pressure from botulinum neurotoxins. PLOS Pathog. 10, e1004177 (2014).
24. R. Jin, A. Rummel, T. Binz, A. T. Brunger, Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature 444, 1092–1095 (2006).
25. M. Elliott, J. Maignel, S. M. Liu, C. Favre-Guilmard, I. Mir, P. Farrow, F. Hornby, S. Marlin, S. Palan, M. Beard, J. Krupp, Augmentation of VAMP-catalytic activity of botulinum neurotoxin serotype B does not result in increased potency in physiological systems. PLOS ONE 12, e0185628 (2017).
26. R. L. Lieber, S. Steinman, I. A. Barash, H. Chambers, Structural and functional changes in spastic skeletal muscle. Muscle Nerve 29, 615–627 (2004).
27. L. R. Smith, E. Pontén, Y. Hedström, S. R. Ward, H. G. Chambers, S. Subramaniam, R. L. Lieber, Novel transcriptional profile in wrist muscles from cerebral palsy patients. BMC Med. Genomics 2, 44 (2009).
28. J. M. J. Dickson, W.-J. Lee, P. R. Shepherd, C. M. Buchanan, Enzyme activity effects of N-terminal his-tag attached to catalytic sub-unit of phosphoinositide-3-kinase. Biosci. Rep. 33, e00079 (2013).
29. R. Tejero, M. Lopez-Manzaneda, S. Arumugam, L. Tabares, Synaptotagmin-2, and -1, linked to neurotransmission impairment and vulnerability in spinal muscular atrophy. Hum. Mol. Genet. 25, 4703–4716 (2016).
30. J.-Y. Li, R. Jahn, A. Dahlström, Synaptotagmin I is present mainly in autonomic and sensory neurons of the rat peripheral nervous system. Neuroscience 63, 837–850 (1994).
31. 2+ -triggered neurotransmitter release. EMBO J. 25, 2039–2050 (2006).
32. A. Hooker, S. Palan, M. Beard, Recombinant botulinum neurotoxin serotype A1 (SXN102342): Protein engineering and process development. Toxicon 123, S40 (2016).
33. W. Kabsch, XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125–132 (2010).
34. T. G. G. Battye, L. Kontogiannis, O. Johnson, H. R. Powell, A. G. W. Leslie, iMOSFLM: A new graphical interface for diffraction-image processing with MOSFLM. Acta Crystallogr. D Biol. Crystallogr. 67, 271–281 (2011).
35. P. Evans, Scaling and assessment of data quality. Acta Crystallogr. D Biol. Crystallogr. 62, 72–82 (2006).
36. Collaborative Computational Project Number 4, The CCP4 suite: Programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760–763 (1994).
37. P. R. Evans, G. N. Murshudov, How good are my data and what is the resolution? Acta Crystallogr. D Biol. Crystallogr. 69, 1204–1214 (2013).
38. S. Swaminathan, S. Eswaramoorthy, Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat. Struct. Biol. 7, 693–699 (2000).
39. A. J. McCoy, R. W. Grosse-Kunstleve, P. D. Adams, M. D. Winn, L. C. Storoni, R. J. Read, Phaser crystallographic software. J. Appl. Cryst. 40, 658–674 (2007).
40. G. N. Murshudov, P. Skubák, A. A. Lebedev, N. S. Pannu, R. A. Steiner, R. A. Nicholls, M. D. Winn, F. Long, A. A. Vagin, REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D Biol. Crystallogr. 67, 355–367 (2011).
41. P. Emsley, B. Lohkamp, W. G. Scott, K. Cowtan, Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501 (2010).
42. V. B. Chen, W. B. Arendall III, J. J. Headd, D. A. Keedy, R. M. Immormino, G. J. Kapral, L. W. Murray, J. S. Richardson, D. C. Richardson, MolProbity: All-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12–21 (2010).
43. S. Lezmi, N. Rokh, G. Saint-Macary, M. Pino, V. Sallez, F. Thevenard, N. Roome, S. Rosolen, Chloroquine causes similar electroretinogram modifications, neuronal phospholipidosis and marked impairment of synaptic vesicle transport in albino and pigmented rats. Toxicology 308, 50–59 (2013).
44. R. S. Broide, J. Rubino, G. S. Nicholson, M. C. Ardila, M. S. Brown, K. R. Aoki, J. Francis, The rat Digit Abduction Score (DAS) assay: A physiological model for assessing botulinum neurotoxin-induced skeletal muscle paralysis. Toxicon 71, 18–24 (2013).
45. A. Pickett, R. O’Keeffe, A. Judge, S. Dodd, The in vivo rat muscle force model is a reliable and clinically relevant test of consistency among botulinum toxin preparations. Toxicon 52, 455–464 (2008).